Stock ORY ORYZON GENOMICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Company Oryzon Genomics S.A.

Equities

ORY

ES0167733015

Biotechnology & Medical Research

Market Closed - BME
Other stock markets
 16:35:10 03/05/2024 BST 		5-day change 1st Jan Change
1.928 EUR +0.94% Intraday chart for Oryzon Genomics S.A. -3.60% +2.12%
04-22 Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat CI
04-08 ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer CI

Business Summary

Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The Company also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.

Number of employees: 44

Managers

Managers TitleAgeSince
Tamara Maes FOU
 Founder - 01/06/00
Carlos Manuel Buesa Arjol CEO
 Chief Executive Officer - 01/06/00
Enric Rello Condomines DFI
 Director of Finance/CFO - 30/04/11
Ana Limon CTO
 Chief Tech/Sci/R&D Officer - 10/01/22
Xavier Perpinya Ribera CMP
 Compliance Officer - 30/04/16
Sonia Paloma Gutierrez CTO
 Chief Tech/Sci/R&D Officer - 30/09/17
Jordi Xaus CTO
 Chief Tech/Sci/R&D Officer - 31/12/13
Douglas Faller CTO
 Chief Tech/Sci/R&D Officer - 27/03/22
Michael Thomas Ropacki PRN
 Corporate Officer/Principal - 31/12/18
Neus Virgili Bernado PRN
 Corporate Officer/Principal - 31/12/08

Members of the board

Members of the board TitleAgeSince
Isabel Aguilera Navarro BRD
 Director/Board Member 62 02/11/15
Carlos Manuel Buesa Arjol CEO
 Chief Executive Officer - 01/06/00
Tamara Maes FOU
 Founder - 01/06/00
Josep María Echarri Torres FOU
 Founder 48 31/08/02
Manuel Lopez-Figueroa BRD
 Director/Board Member - 10/05/20
Ramón Adell Ramón BRD
 Director/Board Member - 02/11/15
Antonio Fornieles Melero BRD
 Director/Board Member 64 02/11/15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 62,969,544 52,765,720 ( 83.80 %) 237,337 ( 0.3769 %) 83.80 %

Shareholders

NameEquities%Valuation
Carlos Manuel Buesa Arjol
5.737 %
3,558,903 5.737 % 7 M €
José-Maria Ventura Ferrero
4.757 %
2,950,736 4.757 % 5 M €
Tamara Maes
4.076 %
2,528,398 4.076 % 5 M €
ORYZON GENOMICS S.A.
1.726 %
1,070,583 1.726 % 2 M €
Josep María Echarri Torres
1.679 %
1,041,768 1.679 % 2 M €
Andbank Wealth Management SGIIC SAU
0.5180 %
321,347 0.5180 % 596 240 €
Inveready Asset Management SGEIC SA
0.3540 %
219,616 0.3540 % 407 484 €
Caixabank Asset Management SGIIC SA
0.1854 %
114,999 0.1854 % 213 374 €
Tressis Gestión SGIIC SA
0.0916 %
56,819 0.0916 % 105 424 €
A&G Fondos SGIIC SA
0.0822 %
51,000 0.0822 % 94 627 €

Holdings

NameEquities%Valuation
ORYZON GENOMICS S.A.
1.73%
 1,070,583 1.73% 1,986,403 $

Company contact information

Oryzon Genomics SA

Calle Sant Ferran 74 Cornellà de Llobregat

08940, Barcelona

+34 93 515 13 13

http://www.oryzon.com
address Oryzon Genomics S.A.(ORY)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.928 EUR
Average target price
6.676 EUR
Spread / Average Target
+246.28%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ORYZON GENOMICS S.A. Stock Oryzon Genomics S.A.
+2.12% 120M
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.86B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.66B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ORY Stock
  4. Company Oryzon Genomics S.A.